Additionally, the administration of CIS and EQ alone or in combination resulted in a significant (p ≤ 0.0001) (p ≤ 0.001) (p ≤ 0.0001) downregulation of the Bcl-2 gene, respectively, with the lowest expression in the combined group, as compared to the untreated EAC group. Here, BCL2 is linked to in situ carcinoma.